Sure, yw.
What the Co-Founder emailed me has been rattling around in my mind.. where he stated basically 4 stages of product types(some with overlaps) and ending up next year considering if and how to proceed in the 4th stage, Pharmaceutical applications.
As mentioned there are different procedures for different molecules('CBDs') and seeds/seed shells in particular for one potential that I am very interested in seeing developed.. the Isolate would be more valuable by a long ways than general Isolation.. exists in lower concentrations than ''General'.
This led me to look at Pharmas, and looking at the JV 'Dragonfly. Where I found Dragonfly as two advisory Board members that have associations with Novartis International AG and Glaxosmithkline pharmaceuticals.
GlaxoSmithKline Plc and Pfizer Inc. is studying CBD..
Novartis, through its generic drug arm Sandoz, has signed an agreement with Tilray Canada to distribute medical cannabis products in countries where it is—or will be—legal.
I suspect these two Pharmas have Advisors at Dragonfly for pertinent reasons.
Such is the depth and breath for Stil's future.
News 
Market Data 
Discover 
